Clinical Trials
7 trialsNCT07249905 2026-05-04
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT06544265 2026-04-14
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Phase 1 Recruiting
NCT07121946 2026-02-10
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
Phase 1 Recruiting
NCT07288879 2026-01-08
DALY II Japan
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT06830031 2025-06-13
C402
Shanghai Exuma Biotechnology Ltd.
Phase 1 Recruiting
NCT05377307 2025-05-13
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Pell Bio-Med Technology Co., Ltd.
Recruiting
NCT06299553 2024-05-22
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
Incyte Biosciences Italy S.r.l
Recruiting